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Abstract
Floating dosage forms are supposed to exhibit an enhanced gastric residence time. Their development is challenging as the prediction of the 
retention potential in humans based on in vitro studies and animal models is difficult.
A strategy to determine the stomach residence time of a floating dosage form with an inherently low density in human without using imaging 
techniques was explored in a self-experiment.
Floating tablets and non-floating controls were prepared containing caffeine as a model drug. The compacts had a pH-dependent enteric-
coating to assess their stomach residence time. Since caffeine is rapidly absorbed in the gastrointestinal tract, the prolonged gastric retention 
of tablets can be demonstrated by a delayed systemic exposure. Caffeine and paraxanthine were determined in capillary blood by liquid 
chromatography coupled to tandem mass spectrometry.
An increase in caffeine and paraxanthine blood levels was observed in human volunteers after 90 to 180 min for the non-floating controls. For 
the floating tablets, no elevated blood concentrations were found in two out of three participants during 8 h of sample collection.
The results demonstrate the technical feasibility of the proposed clinical study protocol. Follow-up clinical trials will be needed to confirm the 
preliminary data on stomach residence time of our floating dosage form.
Keywords: Gastroretentive dosage form; Floating tablet; In vivo gastric residence time; Self-experiment; LC-MS/MS
Abbreviations:
GRDDS - Gastroretentive drug delivery systems; FDDS - Floating drug delivery systems; FCC - Functionalized calcium carbonate; LC-MS/
MS - Liquid chromatography coupled to tandem mass spectrometry
Introduction
Gastroretentive drug delivery systems (GRDDS) offer the possibility 
to prolong and control the residence time of drugs in the stomach and 
the upper part of the small intestine [1]. The reason and need for a 
gastroretentive delivery approach is in most cases dictated by physiological 
necessity [2]. The passage time of conventional oral pharmaceutical 
dosage forms through the stomach is relatively short; thus, GRDDS 
provide a technology to overcome this limitation. Several drug substances, 
e.g. drugs acting locally or being absorbed in the stomach region might 
benefit from enhanced gastric retention times [3]. Floatation has been 
proposed as a mechanism to avoid unpredictable and premature gastric 
emptying of pharmaceutical dosage forms [4]. Due to the low density of 
the drug delivery systems, they float on stomach contents and are retained 
while releasing the drug substance.
During the last years, the development of floating drug delivery systems 
(FDDS) has gained importance. However, there are only few examples of 
clinical trials or marketed GRDDS. One explanation of this shortcoming 
is the fact that it is very difficult to extrapolate from in vitro studies or 
from animal experiments to human. Thus, the phenomenon of flotation 
has to be explored in human to account for the unique anatomical and 
physiological situation in humans. Nevertheless, even complex clinical 
trial protocols often fail to show significantly enhanced gastric residence 
times of FDDS in comparison to non-floating references. A number 
of shortcomings are associated with the clinical evaluation of floating 
dosage forms: the gastric retention time is often determined in the fed 
state; although, high-caloric food is known to delay the gastric emptying 
rate [5]. Additionally, numerous researchers select non-appropriate non-
floating control dosage forms, e.g. immediate release formulations, in 
order to prove prolonged gastric residence times. In some clinical studies, 
only pharmacokinetic data are recorded to provide an indirect estimate of 
the retention time of a dosage form in the stomach. 
A FDDS, which is based on the use of the porous carrier functionalized 
calcium carbonate (FCC), was developed and in vitro flotation in a custom-
built stomach model was demonstrated. Tablet dissolution and buoyancy 
behavior were simulated in silico and provided insight into drug release and 
floating mechanism [6]. But, the extrapolation from these model systems 
to the in vivo situation proofed to be a challenge. Therefore, it was decided 
to evaluate a strategy to test the gastric retention potential in human of 
FCC-based tablets featuring an inherently low density. The aim of the 
present project was to design and evaluate a method in human, which can 
be used to assess and compare the in vivo gastric residence time of floating 
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and non-floating tablets. The compacts contained caffeine as a model 
drug substance and were coated with a pH-dependent enteric-coating. 
Upon retention of a tablet in the acidic environment of the stomach, the 
marker caffeine is thus retained within the tablet. Using minimal amounts 
of capillary blood, the systemic exposure of caffeine and its metabolite 
paraxanthine were determined using liquid chromatography coupled to 
tandem mass spectrometry (LC-MS/MS).
Materials and Methods
Materials
Highly porous functionalized calcium carbonate (FCC VP-DP141 S04, 
Omya, Oftringen, Switzerland) [7] was used as matrix for the preparation 
of tablets with an inherently low density. Two gelation-layer forming 
polymers, water-soluble polyethylene oxide (Polyox™  WSR  301, The 
Dow Chemical Company, Midland, Michigan) and hydroxypropyl 
methylcellulose (Methocel®  K100  Premium  LV, Sandoz Pharma AG, 
Basel, Switzerland) were selected to slow down penetration of liquid 
into the tablet and retard release of the model drug substance caffeine 
(Coffeinum WSF, Böhringer-Ingelheim, Ingelheim, Germany). Citric acid 
(Acid citricummonohydr. pulvis, Hänseler AG, Herisau, Switzerland) 
was chosen as effervescent excipient. The floating formulation was 
prepared by wet-granulation with ethanol 96% (SchweizerhallChemie 
AG, Flawil, Switzerland). The enteric-coating suspension consisted of the 
following materials: Kollicoat MAE 30 DP (BASF, Germany), propylene 
glycol (Hänseler AG, Switzerland), talc (Hänseler AG, Switzerland), and 
titanium dioxide (Hänseler AG, Switzerland).
Methods
Preparation of floating and non-floating tablets: Floating tablet 
formulation was prepared as described 
previously [6]. For in vivo investigation of gastric retention times, 
floating and non-floating tablets using a single punch eccentric press 
(Styl’One, Medelpharm, France) were manufactured. The convex-shaped 
tablets had a curvature radius of 12 mm and a tablet radius of 5mm. The 
cap height was 1.1 mm. The caffeine containing formulation had the same 
composition for both the floating and the non-floating tablets. Tablet 
density was adjusted by using different compaction forces. Since non-
floating tablets had a reduced tablet height, an additional layer of 
130 mg pure FCC was added to obtain identically sized floating and 
non-floating control tablets. Thus, an impact of tablet size on gastric 
retention could be excluded. The characteristics of the prepared 
compacts are summarized in Table 1.
After compaction, the floating and non-floating tablets were coated 
with an enteric-coating in a drum coater (Lab-Coater GC-300, Glatt, 
Switzerland).
Evaluation of in vivo gastric retention in humans: Prior to the in 
vivo evaluation, drug release and flotation behavior of the enteric-coated 
tablets were studied in vitro using a custom-built stomach model [6]. Non-
floating tablets were expected to remain in the gastric region for about 
2 to 3 h [8]. Within this time, the enteric-coating was supposed to remain 
intact; thus, no caffeine and paraxanthine should be observable in the 
blood samples of the volunteers. After being emptied from the stomach, 
the enteric-coating of the compacts should dissolve due to a pH change in 
the intestine, and caffeine as well as paraxanthine plasma concentrations 
increase. In the case of the gastric-coated floating dosage forms, no 
caffeine and paraxanthine should be present in the blood samples of the 
volunteers during 8 h of sample collection.
Study design: The exploratory experiment in human volunteers (n=3) 
using the marker caffeine was brought to the attention of the local ethics 
committee (EKNZ; reference number UBE-15/17) and was considered by 
the committee to be compliant with Swiss legislation. All participants gave 
informed consent prior to the study. 
The study started with a caffeine washout period of 3  days; the 
participants were not allowed to consume any caffeine-containing food. 
In order to evaluate the in vivo gastric retention times, tablets were 
administered at 08:00 a.m. with 300 ml of water after an overnight fasting. 
Every half hour, 300  ml of liquid was provided. A standardized, low-
caloric liquid meal was given 4 h post-administration. Blood samples of 
10 µl were collected via capillary puncture of the fingertip at the indicated 
times. Collected blood samples were diluted with 200  µl methanol 
containing 50 ng/ml of caffeine-d9 as the internal standard and stored at 
-20 °C for further analysis.
Determination of caffeine and its metabolite paraxanthine in 
human plasma: Blood concentrations of caffeine and paraxanthine 
were determined in collected blood samples using LC-MS/MS. The 
analytes were extracted by protein precipitation using methanol (see 
above). Chromatographic separation of sample supernatants was done 
on a Shimadzu HPLC system consisting of an HTS PAL autosampler 
(CTC Analytics AG, Switzerland), two Shimadzu LC-20 AD pumps 
(Shimadzu AG, Switzerland) controlled by a Shimadzu CBM-20A unit, 
and a Shimadzu CTO-20AD column oven. An Atlantis T3 column (2.1 
x 50 mm, Waters AG, Switzerland) was used to separate the analytes. 
Eluent A (0.1% formic acid in water) and eluent B (0.1% formic acid in 
methanol) were delivered at a constant flow of 0.8 ml/min. The following 
gradient was applied: 100% A from 0 to 0.5 min, 50 – 98% B from 0.5 
to 2 min, 98% B from 2 to 2.5 min, 100% A from 2.5 to 2.8 min. Total 
run time was 2.8  min. A thermo stated column oven was set to 60 °C. 
The injection volume was 10 μl. The flow was directed to waste for the 
first and last 0.6 min, to minimize contamination of the MS source. Mass 
spectrometric detection was performed using a triple quadrupole mass 
spectrometer (API4000, Applied Biosystems, Switzerland) operating in 
electrospray-ionization positive-ion mode. Samples were quantified using 
peak area ratios and caffeine-d9 as the internal standard. The assays were linear 
in the concentration ranges of 25 – 1000 ng/ml for caffeine and paraxanthine.
Statistical analysis: A one-sided Grubb’s test for outliers with a 90% 
confidence interval was used in order to detect outliers in the in vivo 
caffeine plasma concentration profiles of floating tablets [9].
Results and Discussion
Figures  1a-1c displays the caffeine and paraxanthine blood 
concentrations measured in human volunteers (n=3) after administration 
of the prepared non-floating enteric-coated tablets. Participants 1, 2, and 3 
showed no elevated caffeine and paraxanthine plasma concentrations up 
to 90, 126, and 175  min, respectively. Thus, the enteric-coating of the 
compacts remained intact within this time period and no caffeine was 
released from the tablets. We assume that the control tablets were located 
in the stomach of the participants during this time.Afterwards,a caffeine 
Formulation Weight (mg)
Diameter 
(mm)
Height 
(mm)
Tablet 
density (g/
cm3)
Floating tablet 399.17 10.02 7.06 0.85
Enteric-coated 
floating atablet 439.77 10.20 7.19 ---
Non-floating tablet 530.10 10.03 7.04 1.13
Enteric-coated non-
floating tablet 564.80 10.21 7.16 ---
Table 1: Properties of the convex-shaped round tablets
 
ForschenSci
O p e n  H U B  f o r  S c i e n t i f i c  R e s e a r c h
Citation: Eberle VA, Donzelli M, Alles R, Puchkov A, Huwyler J (2015) In Vivo Evaluation of a Gastroretentive Drug Delivery System Based on Enteric-
Coated Floating Tablets. Clin Res Open Access 1(2): doi: http://dx.doi.org/10.16966/2469-6714.105
Open Access
3
release from the tablets was observed, resulting in an increase in caffeine 
and paraxanthine levels. It can be concluded that the tablets passed 
through the pylorus into the small intestine. Due to a change in pH in the 
intestinal environment, the enteric-coating started dissolving and caffeine 
was released. Consequently, blood concentrations of caffeine and its 
metabolite paraxanthine increased. For the non-floating tablets, the time 
points at which caffeine and paraxanthine blood concentrations increased 
after administration were comparable for all three study participants. 
The results were in good agreement with another study performed by 
Podczeck et al., where the mean gastric residence time was determined 
to be 91  min for 10  mm tablets administered with a dextrose drink. 
The gastric emptying of food and its influence on the gastric emptying 
of tablets of different dimensions was measured by γ-scintigraphy and 
electrical impedance tomography [10]. 
In contrast, in two out of three participants no increase in caffeine 
and paraxanthine concentrations was measured during 8 h blood sample 
collection for the floating tablets (Figures  2a and 2b). Elevated caffeine 
plasma concentrations were observed at isolated time points. However, 
high caffeine levels were not accompanied by high paraxanthine levels. 
No systemic exposure of caffeine and its metabolite paraxanthine could 
be detected; hence, indicating that the floating dosage forms remained in 
the human stomach.
In the case of one study participant, plasma profiles after administration 
of the floating enteric-coated tablet were similar to the ones of the non-
floating tablet; an increase in caffeine and paraxanthine concentrations 
was seen after approximately 90 min. In this situation, it was not possible 
to determine the reason for failure of the experiment. It might be that 
either the enteric coating of the tablet was defective or that the tablet was 
emptied prematurely from the stomach. 
The pilot experiment did reveal shortcomings of the chosen study 
design. Blood sample collection during 8 h was found to be not sufficient 
in order to detect the increase in caffeine and paraxanthine plasma 
concentrations caused by gastric emptying of the FDDS. First, blood 
sampling time should be extended to at least 24 h to cover longer than 
expected gastric retention times of the tablets. Second, increased caffeine 
levels at isolated time points were obtained in two volunteers. They were 
identified as outliers based on statistical analysis and the absence of a 
concomitant occurrence of the caffeine metabolite paraxanthine. We 
concluded that these outliers were due to a contamination of samples 
by caffeine. In addition, analytical methods have to be used which cover 
both caffeine and its metabolite paraxanthine to exclude blood sample 
contaminations. It might be advisable to validate in a second step the 
position of the tablets in the stomach by e.g. γ-scintigraphy and not to rely 
exclusively on pharmacokinetic analysis of plasma profiles of a marker 
substance.  
The volunteers in this study were provided with low-caloric and liquid 
food in order to exclude the effects of high-caloric meals, which delay 
the gastric emptying process and thus influence the gastric retention of 
pharmaceutical dosage forms. The amount of liquid and food consumed 
during the experiment should therefore be strictly controlled. The 
a) b)
 
C)
 
Figures 1: In vivo caffeine (□) and paraxanthine (■) concentrations in the plasma of three human volunteers after administration of the non-floating 
enteric-coated control tablet. Each data point represents one blood sample.
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volunteers had to maintain an upright position during the duration of the 
experiment; however, they were allowed to move and to do light exercise. 
Our preliminary results seem to suggest that body motion was not a 
critical factor.
Conclusions
Coating of tablets with a pH-dependent enteric-coating seems to be an 
interesting strategy to compare the retention times in the human stomach 
of floating tablets with non-floating reference systems. Non-floating 
controls can be designed to differ only by their density from the test 
tablets. They are superior to immediate-release formulations, which are 
often used as controls. The use of the marker component caffeine seems to 
be an alternative to more expensive imaging techniques.
It was the aim of the present pilot study to demonstrate the technical 
feasibility of a clinical study protocol. Obtained preliminary results 
demonstrate that in vivo characterization in human of a floating dosage 
form is possible. Floating and non-floating control tablets can be compared 
without applying complex imaging technologies.
The performed exploratory study is encouraging and will therefore 
serve as a basis for the preparation of clinical phase I studies to evaluate 
the properties of FCC-based floating dosage forms. In addition, the pilot 
experiment will help to define study conditions and parameters. The 
experience gained from this exploratory study might convince other 
researchers that in vivo performance of FDDS can potentially be explored 
using a relatively simple clinical study design. We hope that our preliminary 
findings might therefore promote the use of this innovative drug delivery 
strategy. Follow-up clinical trials using larger cohorts of volunteers will be 
needed to obtain statistically significant data on stomach residence time 
of our floating dosage form.
Acknowledgements
Rainer Alles, Dr. Maxim Puchkov, and Prof. Dr. Jörg Huwyler have 
contributed equally to the present work. Financial support for the Ph.D. 
thesis of Veronika Eberle was kindly provided by OmyaInternational AG 
(Oftringen, Switzerland).Many thanks to Dr. TanjaStirnimann for her 
support during the study.
References
1. Streubel A, Siepmann J, Bodmeier R (2006) Gastroretentive drug 
delivery systems. Expert Opin Drug Deliv 3: 217–233. 
2. Coupe AJ, Davis SS, Evans DF, Wilding IR (1992) Nocturnal 
scintigraphic imaging to investigate the gastrointestinal transit of 
dosage forms. J Control Release 20: 155–162.
3. Prinderre P, Sauzet C, Fuxen C (2011) Advances in gastro retentive 
drug-delivery systems. Expert Opin Drug Deliv 8: 1189–1203. 
4. Pawar VK, Kansal S, Garg G, Awasthi R, Singodia D, et al. (2011) 
Gastroretentive dosage forms: A review with special emphasis on 
floating drug delivery systems. Drug Deliv 18: 97–110. 
5. Waterman KC (2007) A critical review of gastric retentive controlled 
drug delivery. Pharm Dev Technol 12: 1–10.
6. Eberle VA, Schoelkopf J, Gane PA, Alles R, Huwyler J, et al. (2014) 
Floating gastroretentive drug delivery systems: Comparison of 
experimental and simulated dissolution profiles and floatation 
behavior. Eur J Pharm Sci 58: 34–43. 
7. Stirnimann T, Maiuta N, Gerard D, Alles R, Huwyler J, et al. (2013) 
Functionalized Calcium Carbonate as a Novel Pharmaceutical 
Excipient for the Preparation of Orally Dispersible Tablets. Pharm Res 
30: 1915–1925. 
8. Washington N, Washington C, Wilson CG (2001) The Stomach. In: 
Physiological Pharmaceutics Barriers to Drug Absorption, 2nd edition, 
CRC Press 75–108.
9. Grubbs FE (1969) Procedures for Detecting Outlying Observations in 
Samples. Technometrics 11: 1-21. 
10. Podczeck F, Mitchell CL, Newton JM, Evans D, Short MB (2007) The 
gastric emptying of food as measured by gamma-scintigraphy and 
electrical impedance tomography (EIT) and its influence on the gastric 
emptying of tablets of different dimensions. J Pharm Pharmacol 59: 
1527–1536.
a)
b)
Figures 2: In vivo caffeine (□) and paraxanthine (■) concentrations in 
the plasma of two human volunteers after administration of the floating 
enteric-coated tablet. Each data point represents one blood sample. 
Caffeine outliers identified by a one-sided Grubb’s test for outliers with a 
90% confidence interval are not shown on the graph.
